Microfluidic Application Centre Appoints Gillian Davis to Strategic Commercial Role
News Sep 17, 2007
Dolomite has appointed Dr Gillian Davis to the position of Commercial Director. In this strategic role, Gillian will be instrumental in securing new business opportunities and managing customer relations for Dolomite’s microfluidic capabilities and services.
‘This is an exciting development for us,’ said Mark Gilligan, Managing Director of Dolomite, ‘and reflects the increasing level of interest we are experiencing around the world from customers interested in working with us to bring their microfluidic concepts to market.’
‘I am delighted to welcome Gillian on board, she brings to the company not only a strong background in business development, but also extensive experience of working at the cutting edge of a diverse range of technical disciplines, including materials processing, liquid crystal displays and fibre optic communications. Having people on board with a broad technical background is particularly important to a company, such as Dolomite, which offers a service with an extremely wide application base, including environmental monitoring, clinical diagnostics, drug discovery, nuclear fuels reprocessing and forensic science.’
Dolomite’s key strength lies in being able to offer a complete service to customers from problem conceptualisation and feasibility testing through to full instrument design and development.
The Company says, Gillian’s appointment is just the beginning of Dolomite’s efforts to meet the demand from customers for a partner they can work with to bring their concepts for microfluidic products to market.
Bioengineered Robotic Hand With Its Own Nervous System Will Sense TouchNews
A team of scientists from Florida Atlantic University are developing a first-of-its-kind bioengineered robotic hand that will grow and adapt to its environment.READ MORE
Rap Parody Wins the MicroTAS Video Competition 2017News
First prize awarded to two PhD candidates from Johns Hopkins University in Baltimore, Maryland.READ MORE
Joining Forces to Develop “Nephron-on-a-Chip" to Accelerate Drug Discovery in Kidney DiseaseNews
A new consortium to accelerate the discovery of novel drugs to treat kidney diseases was announced Monday 6 November. The NEPLEX (nephron on a chip with cellular and extracellular matrix complexity) consortium will combine key technologies to develop and build a novel drug discovery device ("Nephron-on-a-Chip").